{"name":"Exegenesis Bio","slug":"exegenesis-bio","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","status":"active","statusNote":"","leadDrug":"","leadIndication":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[],"pipeline":[],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMizwJBVV95cUxOcW1QcjBfb2FyeHJlLXBKSGlGc3hSSGRZMVNTWXY4aGJFLUtzb25wQ0hPb1JQbVl5dFY0UHNXNmR0TGQzVnd3b3JoRC0teXRYM3U0ZERQb182RU95VHJmRXRmbzRranUtYXFDNTV4OWl6MzVkcjdQTHl0SVdRbnRHM3g1Ti1aRVVpd1cteVY3YVdhMks4Wm1NbGlkM09wRHBNTEM2aGJ3VDNrRUxwbGlfdW1hRU1HUjVfVS1iQ2lsNHM3aWV0QXZ1QXo5VnlkRzhGaHpVdDh6cjZUazRRT0VRMTVsZlhKdVZKS084SEhYcklzMFJMNXI4ellXVk9YejhzbDM4X3p4TS1BQ2hjY3Fib2lYTTVyVEtRdEJBY19hLW5fZmRXbWlOZVluTnp4UDJCY3NRcEJ2WUl3T0VtcDViSXlERmZBNXhhTEM1N3hlSQ?oc=5","date":"2026-03-26","type":"regulatory","source":"Barchart.com","summary":"Spinal Muscular Atrophy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by DelveInsight | Genentech, Chugai Pharma, Cytokinetics, Ionis Pharma, Genzyme Corp - B","headline":"Spinal Muscular Atrophy Pipeline 2026: Latest FDA Approvals, Clinical Trials, and Emerging Therapies Assessment by Delve","sentiment":"positive"},{"url":"https://news.google.com/rss/articles/CBMiywJBVV95cUxNal9yb0poS19QYmQ1U3N3bGFzYXJ3VVFoNFZ1bFBEbWFTRGIwbmZOcVdqR0JaSWtsNjR1dVhjNzRaVFJLUzJBSDQtRUpha1VkNW9WSDdlY3pOd2FHeTRHXzhtUEZwMlJYSWFoWUhucWQ1eWdtTEkxNzR1MHlrSGpvUnBkZVE0ODlWQVpoRWhBS19iSUlXY3FsemVFd0xzV2RmOV91MUxSZ2NoWTFnNjFqQXF1QW83YzRTNDZlZ0FNYmZha1dGRjVNbzViMldQSXdyRXl6V1EtVmdRYlZOZHZuTnVQU2ZZR1NZQ0hqRmpuZkw1X09uRHMzd0duNlpOZlhULWMzRnVlajBBb3g0OWJYQnExeGNMc2ZqZHFuMld5YmFObkVMZFF0VXJLT3BpRVRFM3ZUS2Q4TGw4TDhLUUhGS1V4VU1kbS00Q0NR?oc=5","date":"2025-12-01","type":"pipeline","source":"GlobeNewswire","summary":"Geographic Atrophy Market to Surge Significantly During the - GlobeNewswire","headline":"Geographic Atrophy Market to Surge Significantly During the","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwJBVV95cUxQdjA4NjRPMVVoaVhDdmI1M2tpb0pyWlNpd3hTLVRNT01zNXVJc3NPQUpnUUEyV1pqZWNUN2lXdFdDX3dkcUNuTklNWU9NMzNQWGFXcGtRNF94QW5BTkhnYTBqN25OTmpBUVB4YXZTalg5UnN3TkNKZTdqa0ZyM2Njc21EX1MtQ0F6Y19pVHlNeXM0R21OV3dKaU01aHNOSzRBcV9CWWlmNFlHS25hQ3R5S1VKRjQyRmZWOWE2UHNRclJEakY4X1ZLekEtNmViMkFpclRzaldDT1RVaHBoanhNbUJBVG41NUxtTE1XUGxfa3JaZXQwUW54enQ1cFN3NmtwUTJHUlR0c0tHWHRLTDFKSlNuSnlEaUNRa2JqYXk5aGZKQTdOaTk0YTVyUnpKaHRiNDQwNmJkUFFJS2dhckhpN3BxNVkzRjg?oc=5","date":"2025-11-17","type":"pipeline","source":"GlobeNewswire","summary":"Dry Age-related Macular Degeneration Market Poised for - GlobeNewswire","headline":"Dry Age-related Macular Degeneration Market Poised for","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi_gFBVV95cUxNSF8xbF9kOFk3TzBRUzVFNVNFWGRLVFk1VUpiTXVfYWdUN3RyR2NMa1R3QTl1NnhjS0RpME84bHRzbmNieHhvd2JrZjlxazdZSDNHcVFTb3h2YW1jaEpSMjR6cGlSQldjSnJaVkE0NUNyY1FRRElpR1FUNU1Zenl5YVFSUUhmNTdOcmllbEVDZk5IV2xkbTBmcXlyUEh5eW5IZjZ2U2RhRVdSX0FqdzJ1NnNCN1dHYmJNRHk0NDNvNlNiZ0dfSjd5Z2VTaUpZb0dhU3V4a2JJel9RbllGY1E2b2c1d2tWdVh1elpFcW5WOUJfaF9tU3FLaDJ6c2UzUQ?oc=5","date":"2025-01-23","type":"trial","source":"prnewswire.com","summary":"70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight - prnewswire.com","headline":"70+ Key Companies Advancing in Dry Age-Related Macular Degeneration Clinical Trial Therapeutic Space | DelveInsight","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqwFBVV95cUxQYWk1cm8zTHBMcHFYUXlWcTBEdlhrcVBwSE1nR1VxaW9fd2plV04zNlU1LXJXbDlDSDVuaHRGSzBueGVwbXhSLWlYamZXWkN3QUJmZFctWVQxSkFSRGRWOW0yYzRJb3pQLW5oaEtNTFJPVWh3VW8weUhBc0x5Q3ctenhwMm1obDJraEdpc29QQnhNRkwyd1Z1bjNzdVNmQk5oTHRDdm5JT0QtMFk?oc=5","date":"2024-11-12","type":"pipeline","source":"medscape.com","summary":"Dry AMD Highlights From ASRS 2024 - medscape.com","headline":"Dry AMD Highlights From ASRS 2024","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMioAJBVV95cUxPVkRMZTFPNWRnTEliZmx2X2haQUE0ZHJ6TWlGM1V4OElCRjVGMVE4VlpSN0NKLW5hd1pZbHR3QWFQbU1NUHAyWldwd0ZaTVpMY1ZBaFlWU3ZZbHpZVkJsRUtEWnB6XzIyTFlPRGdYVmpHakR6RUVWdWxVcnppcm9neEtOaGIwT0lUZnFrWXJ4TmhuVlZlU1pUcEl2X0Z3VERmdW1ydXA1RmR3WkxqZUtwTUpYTkFISU94YjRYSGRCZnNfaUhRV1l3SzhIN29yd1hGblhqa2lVOEFLMXlxeU1FUVo5clhTY1JpMjUzbFpyOFVxMGctczBwZlZNTjJJMjgwSnppaGM1T2pJbjdBckV4ZnRtTTZVVUl1cG1mS1hlX2w?oc=5","date":"2024-10-22","type":"trial","source":"GlobeNewswire","summary":"Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+ - GlobeNewswire","headline":"Gene Therapy Clinical Trial Pipeline Gains Momentum: 180+","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMikgFBVV95cUxNVjg0Q1dYampjVGFuV2NYMHFOUFhaQndKRWx1aTJZZm9ndG9aUDRwX1kwaF96R2ktRzJ3Z3ljdjVUTVdGTV9JclB4ZFkyLWZLN1QxallYNU1DcDFDSEZjNEVWUHZ2b1lwRmplWTFVYkFjeW04UG9qYkN3ZEFsMWlpS2NraWNHaktUTjNad3FjM1QwZw?oc=5","date":"2024-10-01","type":"pipeline","source":"KrASIA","summary":"Can gene therapy live up to the hype? A look at China’s Exegenesis Bio - KrASIA","headline":"Can gene therapy live up to the hype? A look at China’s Exegenesis Bio","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2024-04-25","type":"trial","source":"businesswire.com","summary":"Exegenesis Bio to Present 9-Patient Data from a Phase 1/2 Clinical Trial of EXG001-307, a Novel rAAV Gene Therapy for Spinal Muscular Atrophy (SMA) Type 1: Improved Head Control and Sitting Without Ex","headline":"Exegenesis Bio to Present 9-Patient Data from a Phase 1/2 Clinical Trial of EXG001-307, a Novel rAAV Gene Therapy for Sp","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMizgJBVV95cUxNY0F6dWlrZk5DekFxRG15YnljVkV0QkV2N21pTlFkUUJtcWdwSjFpYTNFVHFlVzVBcTVjMTdZUzhfNTNLY3JNOW5LN0dnRWh4ZmZOeUROb2FuNUd2NVFqMXlmQnVlUWk4MzduQ3REbzFlQ0dzdXV0N3JZUHMyQnBJOFU4V2RlRzE3a25ldkc5TnljU0RsYVAwc2wzRVg4S2gwSEoyeUlHWUNoSDhMcVFWYTRPNHBnRDFpdEJOZHFRa3RXVWZoTGYxLWRyYWlCSDFKRTRBTGg1cHdMZ3llVzRvcXF1RmpUbVRpa1NXWmpMWnk5ajNvN0VHdXZCTXFzOTVQZlE3dVlKTVVVSk1RVG9oZ3hfd1JoMUttTG11YncxSXVvVzc0aF8xMTRobHdRVHZKM0NuRFZjbmpHLXEwdVhHMnk3dTdrLWEyMV92Tnp3?oc=5","date":"2024-02-19","type":"trial","source":"GlobeNewswire","summary":"Gene Therapies In Ophthalmology Clinical Trial Pipeline - GlobeNewswire","headline":"Gene Therapies In Ophthalmology Clinical Trial Pipeline","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMixwFBVV95cUxPU29VekZtLXdleF9GVlVMdVRzQmRUQ2xqdkVhZFhsU0NHeGxOUzBfc240aVpHVjVBLTluOWJxbVlBWU1JQVVma2JJaGRUNlFjQ3lib0RtaXhHVE9wdzNkaVhRNlo1M1lVRnVZa3pYeFQ0ajk0SDQtYjN0cG1PZXBaVFd1ekNtelpocmJTaXRPeGZGVDdQckUyR1dzMGdIWnRSeEhadHRpenc3eFFoeTd2emtHOHRhWmdIZjFhUjlsRXNBN3VZOVVZ?oc=5","date":"2023-10-06","type":"pipeline","source":"Healio","summary":"Avacincaptad pegol well-tolerated, slows geographic atrophy at 12 months in dry AMD - Healio","headline":"Avacincaptad pegol well-tolerated, slows geographic atrophy at 12 months in dry AMD","sentiment":"neutral"}],"patents":[],"drugCount":0,"phaseCounts":{},"enrichmentLevel":0,"visitCount":6,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}